Abstract:Objective:To discuss ethical review and management of serious adverse events in anti-tumor drug clinical trials in a grade A tertiary cancer hospital for timely and effective protection of subjects.Methods:The main contents and ethical management of ethical review on serious adverse events were retrospectively analyzed including the number, distribution rules, and whether they were reported in time in clinical trials conducted in our hospital in 2021.Results:A total of 1 789 serious adverse events in 259 clinical trials were reported, with more male subjects than female, with an average age of 59.95 years, mainly concentrated in the 50~59 age and 60~69 age groups, accounting for 27.45% and 42.37% respectively. Digestive oncology department, thoracic oncology department and renal cancer melanoma department ranked in the top three for the number of clinical trials and reports of serious adverse events. The highest incidence of serious adverse events was hospitalization at 63.44% and the lowest incidence was disability at 0.39%. The highest proportion of serious adverse events possibly related to clinical trials was 35.72%. Expected serious adverse events accounted for 65.85% versus 34.15% unexpected ones, and the difference between different correlations of serious adverse events whether they were expected or not.was statistically significant. Among the measures taken by the investigator for the test drugs due to serious adverse events, drug discontinuation was the most, accounting for 42.54%, while 3.07% of the trial plans modified the study protocol/informed consent. Serious adverse events reported within 24 hours accounted for 87.20%, and those reported in 24 hours and beyond accounting for 12.80%. A statistically significant difference of the reporting time between the registered and investigator initiated clinical trials was observed.Conclusions:The ethics committee should attach importance to ethical review and management of serious adverse events, pay attention to whether they were reported timely and accurately, strengthen supervision, and effectively protect the safety and interests of the subjects.

Analysis and discussion on the subject complaint in clinical drug trials

Protection of Human Rights in Clinical Trials

Analysis and management of non-compliance/protocol violation or deviation during clinical trials

Ethics Committee' s Management of Noncompliance/Violation or Protocol Deviation Report in Clinical Research

Common Problems in the Ethical Review of Clinical Trial Protocols and the Countermeasures

Human Subjects Protections in Clinical Drug Trials in China

Ethical review and management of serious adverse events in anti-tumor drug clinical trials

Clinical Trials in China: Protection of Subjects’ Rights and Interests

On the Ethical Problem in Drug Clinical Trials

Retrospective analysis on protocol violation of anti-tumor drug clinical trials from the perspective of ethical review

Survey and analysis of insurance for volunteers in clinical trials of new drugs and medical instruments

Practical exploration and research on improving the efficiency of ethical review

Analysis and Countermeasures on Defluxion Cases in Antihypertensive Drug Clinical Trial

Managing Patient Complaints in China: A Qualitative Study in Shanghai

Discussion on problems in conducting the clinical trials on off-label use of drug

Discussion on the construction of management system for clinical trial investigators

Analysis of warning letters issued to investigators by United States Food and Drug Administration

Analysis and Countermeasures of Demands Investigation on Ethical Review Knowledge Training among Clinical Investigators

Ethical analysis in clinical research and experiment

Analysis and research about the management of ethical post approval review in human subject research

Survey on the ethics review in Shanghai Hospital Ethics Committee